An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical Corticosteroids
NCT ID: NCT02627989
Last Updated: 2020-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
55 participants
OBSERVATIONAL
2015-12-10
2017-01-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topical Steroid Formulation and Wet Wraps
NCT02680301
Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis
NCT01691209
Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.
NCT01447758
To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD
NCT05667623
Study of OPA-15406 Ointment in Patients With Atopic Dermatitis
NCT02914548
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diflucortolone valerate (Nerisona/Texmeten)
Adult patients with atopic dermatitis switching from diflucortolone-valerate fatty ointment to ointment (water/oil emulsion) during autumn/ winter (Nov to Feb) or spring/ summer (May to Aug)
Diflucortolone valerate (Nerisona)
Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
Diflucortolone valerate (Texmeten)
Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diflucortolone valerate (Nerisona)
Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
Diflucortolone valerate (Texmeten)
Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are scheduled to change the formulation of the Potency Class II TC from Fatty Ointment to Ointment (Water in Oil; Water per Oil emulsion) as per investigator's routine treatment practice
* Patients who are aged over 20
* Patients who are able to understand and sign a written informed consent
Exclusion Criteria
* Patients with any contraindication to TCs
* Patients who are regarded as ineligible by the investigator
* Patients who are pregnant or breastfeeding
* For Period 2 (Spring-Summer), patients enrolled in the Period 1
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
LEO Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tsu, Mie-ken, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18690
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.